Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (641-650 of 671) with videos related to

Pageof 68
Sort By:
Transplantation and Cellular Therapy|May 23, 2022
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple MyelomaAimaz Afrough, Leonard C Alsfeld, Denái R Milton, et al.
Blood|June 14, 2000
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificitiesR E Champlin, J R Passweg, M J Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched AnalysisNeeraj Saini, Junsheng Ma, Denái R Milton, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Blood Cancer Discovery|October 27, 2025
CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma ModelsPaul Lin, Sunil Acharya, Francia Reyes-Silva, et al.
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
Cell Reports|July 16, 2021
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2019
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched AnalysisAnkur Varma, Dawen Sui, Denái R Milton, et al.
Blood Advances|July 15, 2021
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicityUri Greenbaum, Paolo Strati, Rima M Saliba, et al.
Pageof 68

Showing results (641-650 of 671) with videos related to

Sort By:
Pageof 68
Transplantation and Cellular Therapy|May 23, 2022
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple MyelomaAimaz Afrough, Leonard C Alsfeld, Denái R Milton, et al.
Blood|June 14, 2000
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificitiesR E Champlin, J R Passweg, M J Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched AnalysisNeeraj Saini, Junsheng Ma, Denái R Milton, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Blood Cancer Discovery|October 27, 2025
CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma ModelsPaul Lin, Sunil Acharya, Francia Reyes-Silva, et al.
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
Cell Reports|July 16, 2021
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2019
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched AnalysisAnkur Varma, Dawen Sui, Denái R Milton, et al.
Blood Advances|July 15, 2021
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicityUri Greenbaum, Paolo Strati, Rima M Saliba, et al.
Pageof 68